IVD PRODUCT

ENDO PREDICT®

The second generation of multi-gene for prognostic prediction of breast cancer

Highlights

  • Fifteen years of prognostic validation data provided more accurate recurrence risk assessment
  • Recommended by domestic diagnosis and treatment guidelines
  • Recommended by international authoritative medical guidelines
  • MYRAID GENETICS exclusive strategic partnership
  • Exclusive introduction by Shuwen Biotech.

PREFERRED POPULATION

  • When other clinical indicators are low risk and there are only a few high-risk factors;
  • When elderly patients may be intolerant to chemotherapy;
  • When younger patients were planning to have children or concerned about long term prognosis;
  • When patients intended to be exempted from chemotherapy;

CLINICAL VALUE

To assess 10-year distant recurrence risk for patients receiving Standard endocrine therapy.

Individualized chemotherapy benefit prediction:

To predict the benefit of chemotherapy combined endocrine therapy in reducing 10-year recurrence risk.

Prolonged endocrinotherapy decision:

For patients without recurrence after 5 years of endocrine therapy only, the risk of distant recurrence in 5-15 years should be detected to provide basis to decide prolonging endocrine therapy

Recommended by authoritative guidelines around the world

AJCC-美国癌症联合会
EGTM-欧洲肿瘤标志物工作组
ST.Gallen-圣加仑国际专家共识
ESMO=-欧洲肿瘤内科学会
ASCO-美国临床肿瘤学会
NCCN-美国国家癌症综合网络